日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC

代谢驱动的口服ERα VHL-PROTAC体外/体内分离

Thomas G Hayhow ,Beth Williamson ,Mandy Lawson ,Natalie Cureton ,Erin L Braybrooke ,Andrew Campbell ,Rodrigo J Carbajo ,Azadeh Cheraghchi-Bashi ,Elisabetta Chiarparin ,Coura R Diène ,Charlene Fallan ,David I Fisher ,Frederick W Goldberg ,Lorna Hopcroft ,Philip Hopcroft ,Anne Jackson ,Jason G Kettle ,Teresa Klinowska ,Ulrike Künzel ,Gillian Lamont ,Hilary J Lewis ,Gareth Maglennon ,Scott Martin ,Pablo Morentin Gutierrez ,Christopher J Morrow ,Myria Nikolaou ,J Willem M Nissink ,Patrick O'Shea ,Radoslaw Polanski ,Markus Schade ,James S Scott ,Aaron Smith ,Judith Weber ,Joanne Wilson ,Bin Yang ,Claire Crafter

EstroGene2.0: A multi-omic database of response to estrogens, ER-modulators, and resistance to endocrine therapies in breast cancer

EstroGene2.0:乳腺癌对雌激素、ER 调节剂的反应和对内分泌疗法的抵抗的多组学数据库

Zheqi Li, Fangyuan Chen, Li Chen, Jiebin Liu, Danielle Tseng, Fazal Hadi, Soleilmane Omarjee, Kamal Kishore, Joshua Kent, Joanna Kirkpatrick, Clive D'Santos, Mandy Lawson, Jason Gertz, Matthew J Sikora, Donald P McDonnell, Jason S Carroll, Kornelia Polyak, Steffi Oesterreich, Adrian V Lee3

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

新一代口服选择性雌激素受体降解剂卡米泽司群 (AZD9833) 可抑制 ER+ 乳腺癌的生长并克服内分泌和 CDK4/6 抑制剂耐药性。

Mandy Lawson # ,Natalie Cureton # ,Susana Ros # ,Azadeh Cheraghchi-Bashi ,Jelena Urosevic ,Sophie D'Arcy ,Oona Delpuech ,Michelle DuPont ,David I Fisher ,Eric T Gangl ,Hilary Lewis ,Dawn Trueman ,Neha Wali ,Stuart C Williamson ,Jennifer Moss ,Elodie Montaudon ,Heloise Derrien ,Elisabetta Marangoni ,Ricardo J Miragaia ,Sladjana Gagrica ,Pablo Morentin-Gutierrez ,Thomas A Moss ,Gareth Maglennon ,Daniel Sutton ,Radoslaw Polanski ,Alan Rosen ,Jonathan Cairns ,Pei Zhang ,Mònica Sánchez-Guixé ,Violeta Serra ,Susan E Critchlow ,James S Scott ,Justin P O Lindemann ,Simon T Barry ,Teresa Klinowska ,Christopher J Morrow ,Larissa S Carnevalli

Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer

雌激素受体突变的基因组工程揭示了对抗雌激素的不同反应和乳腺癌的新预后基因特征

Alison Harrod, Chun-Fui Lai, Isabella Goldsbrough, Georgia M Simmons, Natasha Oppermans, Daniela B Santos, Balazs Győrffy, Rebecca C Allsopp, Bradley J Toghill, Kirsty Balachandran, Mandy Lawson, Christopher J Morrow, Manasa Surakala, Larissa S Carnevalli, Pei Zhang, David S Guttery, Jacqueline A Sh

Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer

需要联合抑制 mTOR 和 CDK4/6 才能最佳阻断 E2F 功能并长期抑制雌激素受体阳性乳腺癌的生长

Chrysiis Michaloglou #, Claire Crafter #, Rasmus Siersbaek, Oona Delpuech, Jon O Curwen, Larissa S Carnevalli, Anna D Staniszewska, Urszula M Polanska, Azadeh Cheraghchi-Bashi, Mandy Lawson, Igor Chernukhin, Robert McEwen, Jason S Carroll, Sabina C Cosulich

Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists

激活 ESR1 突变对 ER 拮抗剂的疗效有不同影响

Weiyi Toy, Hazel Weir, Pedram Razavi, Mandy Lawson, Anne U Goeppert, Anne Marie Mazzola, Aaron Smith, Joanne Wilson, Christopher Morrow, Wai Lin Wong, Elisa De Stanchina, Kathryn E Carlson, Teresa S Martin, Sharmeen Uddin, Zhiqiang Li, Sean Fanning, John A Katzenellenbogen, Geoffrey Greene, José Bas